| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $10.2M+12.5% | $9.1M+31.5% | $6.9M+5.3% | $6.5M |
| General and administrative | $7.9M+35.7% | $5.8M-6.5% | $6.2M-29.2% | $8.8M |
| Total operating expenses | $18.1M+21.5% | $14.9M+11.6% | $13.3M-15.3% | $15.7M |
| Loss from operations | -$18.1M-21.5% | -$14.9M-13.7% | -$13.1M+16.9% | -$15.7M |
| Interest expense | -$10K+16.7% | -$12K+20.0% | -$15K-15.4% | -$13K |
| Other income, net | $1.3M+196.8% | $433K-44.8% | $785K-69.6% | $2.6M |
| Total other income, net | $1.3M+202.9% | $421K-45.3% | $770K-47.3% | $1.5M |
| Net loss | -$16.8M-16.2% | -$14.4M-17.4% | -$12.3M+13.7% | -$14.3M |
| Basic weighted average shares used in computing net loss per common share | $55669821.00+3830.2% | $1416471.00+210.6% | $456014.00-48.2% | $880311.00 |
| Diluted weighted average shares used in computing net loss per common share | $55669821.00+3830.2% | $1416471.00-79.3% | $6840213.00+677.0% | $880311.00 |
| Basic net loss per common share | -$0.30+97.1% | -$10.19+62.3% | -$27.01-63.4% | -$16.53 |
| Diluted net loss per common share | -$0.30+97.1% | -$10.19+62.3% | -$27.01-63.4% | -$16.53 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.